Reuters Pharma USA 2024 – Moreno Perugini

Innovation in pharma comes in many forms, but at the end of the day what the industry cares about is results.

At Reuters Pharma USA last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Moreno Perugini, president of the pharmaceutical division of Nestlé Health Sciences.

Perugini was in Philadelphia partly to talk about Vowst, a recently FDA-approved microbiome-based oral treatment for C. diff recurrence. He discusses Vowst specifically and the potential of the microbiome more broadly.

He also talks about the lessons Nestlé Health Sciences has learned about navigating the complex regulatory and reimbursement frameworks in the US as early as possible. The big takeaway? Even with something non-traditional like microbiome therapies, if you can prove it works, people will embrace it.

Plus, they discuss some bigger trends, like the increasing acceptance of real-world evidence and data, policy solutions to reduce healthcare costs, and the growing potential of value-based care.

Check out the full conversation below.